Statins inhibit hepatic HMG‑CoA reductase, lowering LDL by upregulating LDL receptors and reducing ASCVD risk; dosing depends on half‑life, and clinicians must monitor for myopathy risk, especially with interacting dr...
Open this topic in Core Concepts